繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Longeveron发布了自然医学中评估Laromestrocel治疗阿尔茨海默病的2a期临床试验结果

2025-03-11 20:31

  • Phase 2a results demonstrated laromestrocel (Lomecel-B™) improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer's disease
  • This encouraging clinical trial data adds to the body of evidence supporting the safety of single and multiple doses of laromestrocel (Lomecel-B™) treatment for mild Alzheimer's disease and provides indications of efficacy in combating decline of brain volume and potentially cognitive function
  • Laromestrocel (Lomecel-B™) is, to Company's knowledge, the first cellular therapeutic candidate to receive U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) designation for Alzheimer's disease

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。